Calliditas Therapeutics

We're setting our sights on the promising year ahead as we celebrate the milestones reached and progress made in 2024. Our team looks forward to being a part of the Asahi Kasei family, pursuing innovation and for those living with rare #renal diseases

We are incredibly proud of what we've accomplished at Calliditas and excited to begin a new chapter of growth and opportunity with Asahi Kasei. Together, we will continue developing #innovative medicines for those around the world living with rare renal and autoimmune diseases.

#ICYMI, this September Asahi Kasei finalized its acquisition of Calliditas, a strategic move to leverage our combined expertise in nephrology to accelerate the transformation into a global specialty pharmaceutical business. Learn more: https://lnkd.in/eYxkXcqP

Watch as Miami street artist, Rei Ramirez, captures the patient experience of living with IgA Nephropathy (#IgAN) – from the time before until after treatment. #KidneyWk

We'd like to extend our gratitude to our advocacy partners, who support us in honoring our commitment to the IgA nephropathy (#IgAN) community through the work that we do. #KidneyWk The IgA Nephropathy Foundation NephCure National Kidney Foundation International Society of Glomerular Disease

Congratulations to Renee Aguiar-Lucander on being named Executive of the Year - Commercial-Stage Companies at the #ScripAwards2024! Under her leadership, we have advanced innovative solutions to transform the treatment landscape for rare diseases like IgA nephropathy (#IgAN).

Our strong expertise is what makes helping patients possible. Kristi values the deep knowledge and skill of our #CalliditasCommunity and believes this helps our team understand the needs of the communities we support.

Last week we attended #KidneyWk. It was an honor to engage with many nephrologists and experts in IgA Nephropathy (#IgAN). This event provided a valuable opportunity to advance scientific exchange, connect with advocacy groups, and share important data on our pioneering treatment for IgAN. Thank you American Society of Nephrology!

Our late-stage pipeline is based on a first-in-class platform of #NOXinhibitors and our lead compound, setanaxib, inhibits enzymes involved in inflammation and fibrosis pathways. Learn more: https://lnkd.in/gctjYnii

Meet Rei Ramirez, a Cuban-born street artist involved in various exhibitions and collective projects in the art scene of Miami. Rei will be at our American Society of Nephrology #KidneyWk booth depicting, in real time, the lived experiences of patients who are diagnosed with #IgAN and of HCPs who are providing treatment.